This survey of executive decision-makers at over 300 large private employers finds most see rising health costs as a threat to their businesses and believe a broader government role will be necessary to control health costs and ensure coverage.
Top executives at nearly 90% of large employers surveyed believe the cost of providing health benefits to employees will become unsustainable in the next five-to-10 years, and 85% expect the government will be required to intervene to provide coverage …
In this Axios column, Drew Altman explores whether the long struggle with rising health costs has caused the tide to turn in corporate leaders’ attitudes towards government involvement in controlling health spending and whether it is part of a larger s…
In this Axios column, Drew Altman explores whether the long struggle with rising health costs has caused the tide to turn in corporate leaders’ attitudes towards government involvement in controlling health spending and whether it is part of a larger s…
Two new KFF analyses find that lowering the age of Medicare eligibility from 65 to 60 could significantly reduce health spending for employers, who could potentially pass savings to employees in the form of lower premiums or higher wages. Additionally,…
During the presidential campaign, President Biden proposed to lower the age of Medicare eligibility from 65 to 60. This analysis uses claims data for covered medical services from both large employer plans and traditional Medicare to illustrate the pot…
This analysis for the Peterson-KFF Health System Tracker illustrates the potential for employer savings if the age of Medicare eligibility were lowered to 60, as proposed by President Biden during the 2020 campaign.
The COVID-19 pandemic and recent elections are changing the national conversation around expanding health care coverage and reining in rising health care costs. President Biden campaigned on a platform of expanding access to public health coverage in w…
A new KFF analysis finds that a relatively small share of drugs, mainly those without generic or biosimilar competitors, accounted for a disproportionate share of prescription drug spending in Medicare in 2019. This finding suggests that recent proposa…
As policymakers focus attention on proposals to lower prescription drug costs by allowing price negotiation or international reference pricing for a limited number of drugs, this analysis measures the share of total Medicare Part D and Part B prescript…